查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
生物技术人工智慧的全球市场：按功能和最终用户划分（~2029 年）
市场调查报告书
商品编码
1581993

生物技术人工智慧的全球市场：按功能和最终用户划分（~2029 年）

AI in Biotechnology Market by Function & End User - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 386 Pages | 订单完成后即时交付

价格

全球生物技术人工智慧市场规模预计将从 2024 年的 32.3 亿美元成长到 2029 年的 77.5 亿美元，在预测期内复合年增长率高达 19.1%。

由于对个人化治疗和精准医疗的需求不断增加，以及人工智慧在流行病学模型中预测疾病爆发的应用不断增加，预计该市场将会成长。这将有助于公共卫生当局应对并开发更好的疫苗，进一步推动市场成长。对个人化治疗和精准医疗的需求不断增长，导致正在进行的临床试验数量增加。例如，截至 2023 年 10 月，Clinicaltrials.gov 报告了大约 1,584 项使用人工智慧针对各种疾病的临床试验。然而，对人工智慧演算法的有限解释、高昂的实施成本以及对资料隐私和安全的担忧正在限制市场的成长。

调查范围
调查年份 2022-2029
基准年 2023年
预测期 2024-2029
单元 美元
部分 依配置类别/功能/部署模式/最终用户
目标区域 北美、欧洲、亚太地区、拉丁美洲、中东和非洲

“从功能上看，研发部门将在 2023 年占据市场主导地位。”

依功能划分，研发部门在 2023 年所占占比最大。该行业的巨大份额是由个人化医疗、实验室自动化的需求不断增长、预测分析的兴起以及快速药物发现的需求所推动的。

“从最终用户来看，製药公司将在 2023 年占据最大的市场占有率”

从最终用户来看，製药公司占最大份额。随着人口结构的变化，认知能力下降等健康问题变得更加明显，对医疗服务和药物的需求也不断增加。随着老龄化社会预期寿命的延长和医疗保健需求的增加，製药公司将看到巨大的成长机会。此外，製药公司正在研发方面进行大量投资，特别是在药物发现过程中，人工智慧正在用于临床试验中的标靶识别、先导药物最适化和患者分层等任务。

本报告调查了全球生物技术人工智慧市场，并提供了市场概况、对市场成长的各种影响因素的分析、技术和专利趋势、法律制度、案例研究、市场规模趋势和预测以及各种其他资讯。

目录

第一章 简介

第二章调查方法

第三章执行摘要

第 4 章重要考察

第五章市场概况

  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会
    • 任务
  • 生态系分析
  • 案例研究分析
  • 价值链分析
  • 波特五力分析
  • 监管分析
  • 专利分析
  • 技术分析
  • 产业动态
  • 价格分析
  • 主要会议及活动
  • 主要相关利益者和采购标准
  • 影响客户业务的趋势和颠覆
  • 最终用户分析
  • 投资金筹措场景
  • 人工智慧/产生人工智慧对生物技术市场的影响

第六章生物技术的人工智慧市场：依产品类别划分

  • 端对端解决方案
  • 利基解决方案
  • 科技
  • 服务
    • 咨询服务
    • 实施服务/持续 IT 支持
    • 培训和教育服务
    • 售后服务/维修服务

第七章生物技术人工智慧市场：依功能分类

  • 研究与开发
    • 药物发现
    • 临床开发
  • 监理合规性
  • 製造/供应链
    • 供应链规划
    • 库存管理
    • 物流最佳化
    • 需求预测
    • 预测性维护
    • 其他的
  • 产品发布/商业性功能
    • 释放调整
    • 病人参与
    • 行销业务
    • 预测定价
  • 上市后监测/病患支持
    • 用药依从性
    • 不利事件报告
    • 病患监测
    • 合规监控
    • 患者援助计划
  • 公司
    • 风险管理
    • 合规监控
    • 优化销售队伍
    • 其他的

第八章生物技术领域的人工智慧市场：依实施模式分类

  • 云端基础的解决方案
    • 公共云端
    • 私有云端
    • 多重云端
    • 混合云端
  • 本地解决方案

第九章生物技术的人工智慧市场：按最终用户划分

  • 製药公司
  • 生技公司
  • 研究机构/实验室
  • 医疗提供者
  • CRO

第10章生物技术人工智慧市场：按地区

  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第十一章竞争格局

  • 主要企业/主要企业策略
  • 收益分析
  • 市场占有率分析
  • 企业评价矩阵：主要企业
  • 公司评估矩阵：Start-Ups企业/中小企业
  • 公司评价及财务指标
  • 品牌/产品比较
  • 竞争场景

第十二章 公司简介

  • 主要企业
    • NVIDIA CORPORATION
    • ILLUMINA, INC.
    • EXSCIENTIA
    • SCHRODINGER, INC.
    • RECURSION PHARMACEUTICALS, INC.
    • SOPHIA GENETICS
    • PREDICTIVE ONCOLOGY
    • BENEVOLENTAI
    • EUROFINS DISCOVERY
    • XTALPI INC.
    • DNANEXUS, INC.
    • NUMEDII, INC.
    • BPGBIO, INC.
    • IKTOS.
    • INSILICO MEDICINE
    • LOGICA
    • AMERICAN CHEMICAL SOCIETY
    • AGANITHA AI INC.
  • Start-Ups/中小企业
    • VERISIM LIFE
    • VALO HEALTH
    • TEMPUS AI, INC.
    • LIFEBIT BIOTECH LTD.
    • GENOOX
    • DATA4CURE, INC.
    • DEEP GENOMICS

第十三章附录

Product Code: HIT 9205

The global AI in biotechnology market is projected to reach USD 7.75 billion by 2029 from USD 3.23 billion in 2024, at a high CAGR of 19.1% during the forecast period. The market is expected to grow as a result of the increasing demand for personalized therapies and precision medicines, and the growing applications of AI in epidemiological models for predicting disease outbreaks. It helps public health officials to respond and develop better vaccines which further drives market growth. The increasing demand for personalized therapies and precision medicine has led to an increasing number of clinical trials performed. For instance, as of October 2023, around 1584 clinical trials performed using AI for various diseases were reported to Clincaltrials.gov. However, the limited interpretability of AI algorithms, high implementation cost and data privacy & security concerns are some of the restraining factors for the market growth.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredMillion/Billion (USD)
SegmentsBy Offering, Function, Deployment Mode, and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America and Middle East and Africa

"Based on function, research & development segment dominated the AI in biotechnology market in 2023"

The AI in biotechnology market by function is broadly divided into six segments: research & development, regulatory compliance, manufacturing & supply chain, launch & commercial, and post-market surveillance & patient support. The research & development segment accounted for the largest share of the global AI in biotechnology market in 2023. The large share of this segment can be attributed to the rising demand for personalized medicine, automation in labs, the rise of predictive analytics, and the need for faster drug discovery. an increase in the number of AI-discovered molecules in clinical trials significantly augments market growth. For instance, AI-native Biotechs and their partners in the pharmaceutical industry have entered an increasing number of molecules for AI-driven clinical trials (Source: Elsevier B.V.). In 2023, there were around 67 reported ongoing trials, and this number has increased from 2014 with around 60% year-over-year compound growth.

"In 2023, the pharmaceutical companies held the largest market share among end users."

Based on end user, pharmaceutical companies hold the largest share of the AI in biotechnology market. There are emerging health problems, notably cognitive decline that led to high healthcare services and medication demands, associated with such demographic shifts. Pharmaceutical companies will experience huge growth opportunities as life expectancy increases, thereby raising the increasing healthcare demands of this aging population. Additionally, massive investments are being made by pharmaceutical companies into research and development, particularly drug discovery and development processes wherein AI is utilized for tasks like target identification, lead optimization, and patient stratification in clinical trials.

"In 2023, Europe was the second largest regional market for AI in the biotechnology market."

In 2023, Europe held the second-highest share of the AI in biotechnology market. This dominance is attributed to a substantial increase in investment in Europe for AI, with a growing number of patent filings for biotechnology-related medical technology. In the year 2022, the European Patent Office (EPO) published over 10,000 AI patent applications, which highlights an increased focus on AI solutions in biotechnology. In March 2023, the UK government pledged investment in nine promising AI healthcare technologies to speed up research and development. Moreover, in August 2023, the government launched 22 new projects to explore the application of AI in healthcare. All these initiatives represent Europe's determination to spearhead applications of AI in the biotechnology sector.

The break-down of primary participants is as mentioned below:

  • By Company Type - Tier 1: 45%, Tier 2: 30%, and Tier 3: 25%
  • By Designation - C-level: 42%, Director-level: 31%, and Others: 27%
  • By Region - North America: 32%, Europe: 32%, Asia Pacific: 26%, Middle East & Africa: 5%, Latin America: 5%

NVIDIA Corporation (US), Illumina, Inc. (US), Exscientia plc (UK), Schrodinger, Inc. (US), Recursion Pharmaceuticals, Inc. (US), SOPHiA GENETICS (Switzerland), Predictive Oncology. (US), Deep Genomics. (Canada), ), Data4Cure, Inc. (US), Genoox (US), BenevolentAI (US), and DNAnexus, Inc. (US) are some of the key players in the AI in biotechnology market.

The study includes an in-depth competitive analysis of these key players in AI in biotechnology market, with their company profiles, recent developments, and key market strategies.

Research Coverage:

The report analyses the AI in biotechnology market. It aims to estimate the market size and future growth potential of various market segments based on offering (end-to-end solutions, niche solutions, technology providers, and services), function (research & development [R&D], regulatory compliance, manufacturing & supply chain, launch & commercial, post-market surveillance & patient support, and corporate), deployment mode (cloud-based, and on-premise), end-user (pharmaceutical companies, biotechnology companies, research institutes and labs, healthcare providers, and contract research organizations [CRO]), and region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the AI in biotechnology market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, and services; key strategies; partnerships, collaborations, acquisitions, expansion, agreements, investment, and product launches associated with the AI in biotechnology market. Competitive analysis of upcoming startups in the AI in biotechnology market ecosystem is covered in this report.

Reasons to Buy the Report

This report will enrich established firms and new entrants/smaller firms to gauge the market's pulse, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.

This report provides insights on:

Analysis of key drivers: (growing cross-industry collaborations and partnerships, growing need to reduce the time and cost of drug discovery and development, rising adoption of AI in precision medicine, improving computing power, and declining hardware cost), restraints (high implementation costs of AI limit adoption in biotechnology, especially for SMEs and emerging economies, data privacy risks and compliance challenges for AI in biotechnology), opportunities (integrating AI and big data in precision medicine for biotechnology advancement, surge in biotechnology investments enhances opportunities for AI to accelerate drug discovery innovations, innovation across healthcare, agriculture, and environmental science for global growth), and challenges (data quality and interpretability issues that hinder AI integration and trustworthiness, AI deployment in biotechnology hindered by talent shortages and evolving regulatory challenges) influencing the growth of the AI in biotechnology market.

  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the AI in biotechnology market.
  • Market Development: Comprehensive information on the lucrative emerging markets, by offering, function, deployment mode, end-user, and region.
  • Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the AI in biotechnology market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the AI in biotechnology market including NVIDIA Corporation (US), Illumina, Inc. (US), Exscientia (UK), Schrodinger, Inc. (US), Recursion Pharmaceuticals, Inc. (US), SOPHiA GENETICS (Switzerland), Predictive Oncology. (US),Deep Genomics. (Canada), Exscientia (US), and Data4Cure, Inc.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key data from primary sources
      • 2.1.2.2 Insights from primary experts
  • 2.2 MARKET SIZE ESTIMATION
  • 2.3 DATA TRIANGULATION
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 RESEARCH ASSUMPTIONS
  • 2.6 LIMITATIONS
    • 2.6.1 METHODOLOGY-RELATED LIMITATIONS
    • 2.6.2 SCOPE-RELATED LIMITATIONS
  • 2.7 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 AI IN BIOTECHNOLOGY MARKET OVERVIEW
  • 4.2 AI IN BIOTECHNOLOGY MARKET, BY REGION
  • 4.3 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER & REGION
  • 4.4 AI IN BIOTECHNOLOGY MARKET: GEOGRAPHIC SNAPSHOT
  • 4.5 AI IN BIOTECHNOLOGY MARKET: DEVELOPED VS. EMERGING ECONOMIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing cross-industry collaborations and partnerships
      • 5.2.1.2 Growing need to reduce time and cost of drug discovery and development
      • 5.2.1.3 Rising adoption of AI in precision medicine
      • 5.2.1.4 Improving computing power and declining hardware cost
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High implementation costs of AI limit adoption in biotechnology, especially for SMEs and emerging economies
      • 5.2.2.2 Data privacy risks and compliance challenges for AI in biotechnology
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Integrating AI and big data in precision medicine for biotechnology advancement
      • 5.2.3.2 Surge in biotechnology investments enhances opportunities for AI to accelerate drug discovery innovations
      • 5.2.3.3 Innovation across healthcare, agriculture, and environmental science for global growth
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Data quality and interpretability issues that hinder AI integration and trustworthiness
      • 5.2.4.2 AI deployment in biotechnology hindered by talent shortages and evolving regulatory challenges
  • 5.3 ECOSYSTEM ANALYSIS
  • 5.4 CASE STUDY ANALYSIS
    • 5.4.1 LEVERAGED NVIDIA DGX CLOUD FOR RAPID TRAINING OF PROTEIN MODELS
    • 5.4.2 IMPLEMENTED END-TO-END NGS WORKFLOW FOR EFFICIENT GENETIC VARIANT DETECTION
    • 5.4.3 ACCELERATED DRUG DISCOVERY WITH GENERATIVE AI AND STREAMLINED WORKFLOWS
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 PORTER'S FIVE FORCES ANALYSIS
    • 5.6.1 BARGAINING POWER OF SUPPLIERS
    • 5.6.2 BARGAINING POWER OF BUYERS
    • 5.6.3 THREAT OF SUBSTITUTES
    • 5.6.4 THREAT OF NEW ENTRANTS
    • 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.7 REGULATORY ANALYSIS
    • 5.7.1 REGULATORY LANDSCAPE
      • 5.7.1.1 North America
      • 5.7.1.2 Europe
      • 5.7.1.3 Asia Pacific
      • 5.7.1.4 Latin America
      • 5.7.1.5 Middle East & Africa
    • 5.7.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.8 PATENT ANALYSIS
    • 5.8.1 PATENT PUBLICATION TRENDS FOR AI IN BIOTECHNOLOGY
    • 5.8.2 JURISDICTION AND TOP APPLICANT ANALYSIS
  • 5.9 TECHNOLOGY ANALYSIS
    • 5.9.1 KEY TECHNOLOGIES
      • 5.9.1.1 Natural Language Processing (NLP)
      • 5.9.1.2 Predictive analytics
    • 5.9.2 COMPLEMENTARY TECHNOLOGIES
      • 5.9.2.1 Cloud computing
      • 5.9.2.2 Big data analytics
  • 5.10 INDUSTRY TRENDS
    • 5.10.1 EVOLUTION OF AI IN BIOTECHNOLOGY
    • 5.10.2 COMPUTER-AIDED DRUG DESIGN AND AI
  • 5.11 PRICING ANALYSIS
    • 5.11.1 INDICATIVE PRICING ANALYSIS, BY DRUG DISCOVERY PROCESS
    • 5.11.2 AVERAGE SELLING PRICE TREND, BY REGION
  • 5.12 KEY CONFERENCES & EVENTS, 2024-2025
  • 5.13 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.13.1 BUYING CRITERIA
  • 5.14 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.15 END-USER ANALYSIS
    • 5.15.1 UNMET NEEDS
    • 5.15.2 END-USER EXPECTATIONS
  • 5.16 INVESTMENT & FUNDING SCENARIO
  • 5.17 IMPACT OF AI/GEN AI ON AI IN BIOTECHNOLOGY MARKET
    • 5.17.1 KEY USE CASES
    • 5.17.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION
      • 5.17.2.1 Case study: Accelerated biomarker discovery and clinical trial optimization
    • 5.17.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS
      • 5.17.3.1 Drug discovery and development market
      • 5.17.3.2 Genomics and bioinformatics market
      • 5.17.3.3 Medical imaging & diagnostics market
    • 5.17.4 USER READINESS & IMPACT ASSESSMENT
      • 5.17.4.1 User readiness
        • 5.17.4.1.1 Pharmaceutical companies
        • 5.17.4.1.2 Biotechnology companies
      • 5.17.4.2 Impact assessment
        • 5.17.4.2.1 User A: Pharmaceutical companies
          • 5.17.4.2.1.1 Implementation
          • 5.17.4.2.1.2 Impact
        • 5.17.4.2.2 User B: Biotechnology companies
          • 5.17.4.2.2.1 Implementation
          • 5.17.4.2.2.2 Impact

6 AI IN BIOTECHNOLOGY MARKET, BY OFFERING

  • 6.1 INTRODUCTION
  • 6.2 END-TO-END SOLUTIONS
    • 6.2.1 GROWING USE OF ADVANCED ALGORITHMS TO IMPROVE PRECISION AND EFFICIENCY TO BOOST MARKET GROWTH
  • 6.3 NICHE SOLUTIONS
    • 6.3.1 ABILITY OF NICHE SOLUTIONS TO ADDRESS SPECIFIC CHALLENGES WITHIN DRUG DISCOVERY TO SUPPORT ADOPTION
  • 6.4 TECHNOLOGIES
    • 6.4.1 ABILITY OF TECHNOLOGIES TO ENHANCE DRUG DISCOVERY, PERSONALIZED MEDICINE, AND DATA ANALYTICS TO FUEL GROWTH
  • 6.5 SERVICES
    • 6.5.1 CONSULTING SERVICES
      • 6.5.1.1 Increasing efficiency of research processes and cost savings to boost adoption of consulting services
    • 6.5.2 IMPLEMENTATION SERVICES & ONGOING IT SUPPORT
      • 6.5.2.1 Increasing precision and efficiency in IT support services to boost demand
    • 6.5.3 TRAINING & EDUCATION SERVICES
      • 6.5.3.1 Need for skilled talent to drive market growth
    • 6.5.4 POST-SALES & MAINTENANCE SERVICES
      • 6.5.4.1 Complexity of AI systems and need for improvement in AI algorithms to boost market

7 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION

  • 7.1 INTRODUCTION
  • 7.2 RESEARCH & DEVELOPMENT
    • 7.2.1 DRUG DISCOVERY
      • 7.2.1.1 Molecular design & optimization
        • 7.2.1.1.1 Increased efficiency in drug discovery with molecular design & optimization to drive market growth
      • 7.2.1.2 Biomarker discovery
        • 7.2.1.2.1 Ability to analyze large data sets with AI-enabled biomarker discovery to boost demand for
      • 7.2.1.3 Structure-activity relationship (SAR) modeling
        • 7.2.1.3.1 Improved data analysis, predictive modeling, and compound optimization for drug candidates with SAR to fuel growth
    • 7.2.2 CLINICAL DEVELOPMENT
      • 7.2.2.1 Trial design
        • 7.2.2.1.1 Ability of AI to improve trial design through simulations and patient stratification to favor market
      • 7.2.2.2 Site selection
        • 7.2.2.2.1 Optimized process of selecting clinical trial sites to fuel growth
      • 7.2.2.3 Recruitment
        • 7.2.2.3.1 Enhanced process of selecting and enrolling participants for clinical trials to drive demand
      • 7.2.2.4 Clinical data assessment
        • 7.2.2.4.1 Ability of clinical data assessment to enhance efficiency and accuracy of data interpretation to propel market
      • 7.2.2.5 Predictive toxicity & risk monitoring
        • 7.2.2.5.1 Ability of data integration and predictive modeling to create comprehensive risk profiles for drug candidates to support market
      • 7.2.2.6 Monitoring & drug adherence
        • 7.2.2.6.1 Enhanced patient compliance with monitoring & drug adherence to drive market growth
      • 7.2.2.7 Real-world evidence (RWE) analysis
        • 7.2.2.7.1 Enhanced safety monitoring & economic evaluation with RWE analysis to propel growth
  • 7.3 REGULATORY COMPLIANCE
    • 7.3.1 ABILITY OF AI TO ENSURE REGULATORY COMPLIANCE IN CLINICAL TRIALS TO SUPPORT GROWTH
  • 7.4 MANUFACTURING & SUPPLY CHAIN
    • 7.4.1 SUPPLY CHAIN PLANNING
      • 7.4.1.1 Increasing demand for real-time data analytics to accelerate market growth
    • 7.4.2 INVENTORY MANAGEMENT
      • 7.4.2.1 Automating stock tracking and replenishment with advanced analytics to fuel growth
    • 7.4.3 LOGISTICS OPTIMIZATION
      • 7.4.3.1 Ability of AI to drive collaboration and transparency in biotechnology logistics to aid growth
    • 7.4.4 DEMAND FORECASTING
      • 7.4.4.1 Ability to integrate data for reliable demand forecasts to fuel growth
    • 7.4.5 PREDICTIVE MAINTENANCE
      • 7.4.5.1 Boosting equipment reliability with AI-powered predictive maintenance to drive demand
    • 7.4.6 OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS
  • 7.5 LAUNCH & COMMERCIAL
    • 7.5.1 LAUNCH COORDINATION
      • 7.5.1.1 Growing product launch success rates through predictive analytics to boost adoption
    • 7.5.2 PATIENT ENGAGEMENT
      • 7.5.2.1 Advantages such as real-time patient feedback for better health outcomes to support growth
    • 7.5.3 MARKETING OPERATIONS
      • 7.5.3.1 Enhanced marketing performance with AI to boost market
    • 7.5.4 PREDICTIVE PRICING
      • 7.5.4.1 Ability of AI to enhance pricing accuracy to drive adoption
  • 7.6 POST-MARKETING SURVEILLANCE & PATIENT SUPPORT
    • 7.6.1 MEDICATION ADHERENCE
      • 7.6.1.1 Growing demand for personalized healthcare to drive market
    • 7.6.2 ADVERSE EVENT REPORTING
      • 7.6.2.1 Advantages such as faster post-market surveillance and enhanced drug safety to drive demand
    • 7.6.3 PATIENT MONITORING
      • 7.6.3.1 Rise of remote healthcare solutions to boost demand
    • 7.6.4 COMPLIANCE MONITORING
      • 7.6.4.1 Increasing complexity of regulatory requirements to drive adoption
    • 7.6.5 PATIENT SUPPORT PROGRAMS
      • 7.6.5.1 Growing interest in patient-centered care to support growth
  • 7.7 CORPORATE
    • 7.7.1 RISK MANAGEMENT
      • 7.7.1.1 Rising expenditure for drug development to support growth
    • 7.7.2 COMPLIANCE MONITORING
      • 7.7.2.1 Strict guidelines from bodies to aid growth
    • 7.7.3 SALES FORCE OPTIMIZATION
      • 7.7.3.1 Need for data-driven decision-making to boost adoption of sales force optimization
    • 7.7.4 OTHER CORPORATE FUNCTIONS

8 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE

  • 8.1 INTRODUCTION
  • 8.2 CLOUD-BASED SOLUTIONS
    • 8.2.1 PUBLIC CLOUD
      • 8.2.1.1 Need to reduce dependency on expensive on-premise infrastructure to boost demand
    • 8.2.2 PRIVATE CLOUD
      • 8.2.2.1 Need for enhanced security and data protection to drive market growth
    • 8.2.3 MULTI-CLOUD
      • 8.2.3.1 Enhanced flexibility & cost optimization to support market growth
    • 8.2.4 HYBRID CLOUD
      • 8.2.4.1 Cost efficiency and flexibility of hybrid cloud to fuel growth
  • 8.3 ON-PREMISE SOLUTIONS
    • 8.3.1 ADVANTAGES SUCH AS DATA SECURITY AND PRIVACY AND COMPLIANCE WITH REGULATIONS TO FAVOR GROWTH

9 AI IN BIOTECHNOLOGY MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 PHARMACEUTICAL COMPANIES
    • 9.2.1 INNOVATION AND EFFICIENCY ASSOCIATED WITH AI INTEGRATION IN DRUG DISCOVERY & DEVELOPMENT TO BOOST ADOPTION
  • 9.3 BIOTECHNOLOGY COMPANIES
    • 9.3.1 ABILITY OF AI-DRIVEN INNOVATIONS TO ACCELERATE PERSONALIZED MEDICINE AND DRUG DISCOVERY TO SUPPORT GROWTH
  • 9.4 RESEARCH INSTITUTES & LABS
    • 9.4.1 STRATEGIC INVESTMENTS AND COLLABORATIONS TO PROPEL AI ADVANCEMENTS IN RESEARCH INSTITUTES AND LABS
  • 9.5 HEALTHCARE PROVIDERS
    • 9.5.1 IMPROVED PATIENT OUTCOMES TO SUPPORT ADOPTION
  • 9.6 CONTRACT RESEARCH ORGANIZATIONS (CROS)
    • 9.6.1 ABILITY OF AI TECHNOLOGIES TO ACCELERATE CLINICAL TRIALS AND IMPROVE PATIENT RECRUITMENT TO FUEL GROWTH

10 AI IN BIOTECHNOLOGY MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 10.2.2 US
      • 10.2.2.1 Increasing investments and partnerships to drive market
    • 10.2.3 CANADA
      • 10.2.3.1 Availability of advanced facilities and shorter approval times for drug candidates to drive market
  • 10.3 EUROPE
    • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 10.3.2 GERMANY
      • 10.3.2.1 Increased funding in start-ups to drive uptake of AI in biotechnology
    • 10.3.3 UK
      • 10.3.3.1 Increasing investments and government fund allocations to drive market
    • 10.3.4 FRANCE
      • 10.3.4.1 Government initiatives in France to support market growth
    • 10.3.5 ITALY
      • 10.3.5.1 Growing investments to create opportunities for market growth
    • 10.3.6 SPAIN
      • 10.3.6.1 Increasing need for personalized medicine and data-driven healthcare to increase adoption rate in market
    • 10.3.7 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 10.4.2 JAPAN
      • 10.4.2.1 Accelerating AI-driven drug discovery and biotechnology innovation to drive market in Japan
    • 10.4.3 CHINA
      • 10.4.3.1 Rising foreign investments to drive market in China
    • 10.4.4 INDIA
      • 10.4.4.1 Increasing number of start-ups and support from government to propel market
    • 10.4.5 SOUTH KOREA
      • 10.4.5.1 Significant advances in AI integration for R&D to fuel growth
    • 10.4.6 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 10.5.2 BRAZIL
      • 10.5.2.1 Funding of biotech companies to drive market in Brazil
    • 10.5.3 MEXICO
      • 10.5.3.1 Investment inflows and strengthening AI-related education to drive market in Mexico
    • 10.5.4 REST OF LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    • 10.6.2 GCC COUNTRIES
      • 10.6.2.1 Increase in healthcare investments to support market growth
    • 10.6.3 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 11.3 REVENUE ANALYSIS, 2019-2023
  • 11.4 MARKET SHARE ANALYSIS, 2023
    • 11.4.1 RANKING OF KEY MARKET PLAYERS
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
    • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 11.5.5.1 Company footprint
      • 11.5.5.2 Component footprint
      • 11.5.5.3 Application footprint
      • 11.5.5.4 End-user footprint
      • 11.5.5.5 Region footprint
  • 11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 RESPONSIVE COMPANIES
    • 11.6.3 DYNAMIC COMPANIES
    • 11.6.4 STARTING BLOCKS
    • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 11.7 COMPANY VALUATION & FINANCIAL METRICS
  • 11.8 BRAND/PRODUCT COMPARISON
  • 11.9 COMPETITIVE SCENARIO
    • 11.9.1 PRODUCT LAUNCHES & UPGRADES
    • 11.9.2 DEALS
    • 11.9.3 EXPANSIONS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
    • 12.1.1 NVIDIA CORPORATION
      • 12.1.1.1 Business overview
      • 12.1.1.2 Products offered
      • 12.1.1.3 Recent developments
        • 12.1.1.3.1 Product launches
        • 12.1.1.3.2 Deals
      • 12.1.1.4 MnM view
        • 12.1.1.4.1 Right to win
        • 12.1.1.4.2 Strategic choices
        • 12.1.1.4.3 Weaknesses & competitive threats
    • 12.1.2 ILLUMINA, INC.
      • 12.1.2.1 Business overview
      • 12.1.2.2 Products offered
      • 12.1.2.3 Recent developments
        • 12.1.2.3.1 Product launches
        • 12.1.2.3.2 Deals
      • 12.1.2.4 MnM view
        • 12.1.2.4.1 Right to win
        • 12.1.2.4.2 Strategic choices
        • 12.1.2.4.3 Weaknesses & competitive threats
    • 12.1.3 EXSCIENTIA
      • 12.1.3.1 Business overview
      • 12.1.3.2 Products offered
      • 12.1.3.3 Recent developments
        • 12.1.3.3.1 Product launches
        • 12.1.3.3.2 Deals
        • 12.1.3.3.3 Other developments
      • 12.1.3.4 MnM view
        • 12.1.3.4.1 Right to win
        • 12.1.3.4.2 Strategic choices
        • 12.1.3.4.3 Weaknesses & competitive threats
    • 12.1.4 SCHRODINGER, INC.
      • 12.1.4.1 Business overview
      • 12.1.4.2 Products offered
      • 12.1.4.3 Recent developments
        • 12.1.4.3.1 Product upgrades
        • 12.1.4.3.2 Deals
    • 12.1.5 RECURSION PHARMACEUTICALS, INC.
      • 12.1.5.1 Business overview
      • 12.1.5.2 Products offered
      • 12.1.5.3 Recent developments
        • 12.1.5.3.1 Deals
        • 12.1.5.3.2 Expansions
    • 12.1.6 SOPHIA GENETICS
      • 12.1.6.1 Business overview
      • 12.1.6.2 Products offered
      • 12.1.6.3 Recent developments
        • 12.1.6.3.1 Product launches
        • 12.1.6.3.2 Deals
    • 12.1.7 PREDICTIVE ONCOLOGY
      • 12.1.7.1 Business overview
      • 12.1.7.2 Products offered
      • 12.1.7.3 Recent developments
        • 12.1.7.3.1 Product launches
        • 12.1.7.3.2 Deals
    • 12.1.8 BENEVOLENTAI
      • 12.1.8.1 Business overview
      • 12.1.8.2 Products offered
      • 12.1.8.3 Recent developments
        • 12.1.8.3.1 Deals
    • 12.1.9 EUROFINS DISCOVERY
      • 12.1.9.1 Business overview
      • 12.1.9.2 Products offered
      • 12.1.9.3 Recent developments
        • 12.1.9.3.1 Product launches
        • 12.1.9.3.2 Deals
        • 12.1.9.3.3 Expansions
    • 12.1.10 XTALPI INC.
      • 12.1.10.1 Business overview
      • 12.1.10.2 Products offered
      • 12.1.10.3 Recent developments
        • 12.1.10.3.1 Deals
    • 12.1.11 DNANEXUS, INC.
      • 12.1.11.1 Business overview
      • 12.1.11.2 Products offered
      • 12.1.11.3 Recent developments
        • 12.1.11.3.1 Deals
        • 12.1.11.3.2 Other developments
    • 12.1.12 NUMEDII, INC.
      • 12.1.12.1 Business overview
      • 12.1.12.2 Products offered
    • 12.1.13 BPGBIO, INC.
      • 12.1.13.1 Business overview
      • 12.1.13.2 Products offered
      • 12.1.13.3 Recent developments
        • 12.1.13.3.1 Deals
    • 12.1.14 IKTOS.
      • 12.1.14.1 Business overview
      • 12.1.14.2 Products offered
      • 12.1.14.3 Recent developments
        • 12.1.14.3.1 Deals
    • 12.1.15 INSILICO MEDICINE
      • 12.1.15.1 Business overview
      • 12.1.15.2 Products offered
    • 12.1.16 LOGICA
      • 12.1.16.1 Business overview
      • 12.1.16.2 Products offered
    • 12.1.17 AMERICAN CHEMICAL SOCIETY
      • 12.1.17.1 Business overview
      • 12.1.17.2 Products offered
    • 12.1.18 AGANITHA AI INC.
      • 12.1.18.1 Business overview
      • 12.1.18.2 Products offered
      • 12.1.18.3 Recent developments
        • 12.1.18.3.1 Deals
  • 12.2 START-UP/SME PLAYERS
    • 12.2.1 VERISIM LIFE
    • 12.2.2 VALO HEALTH
    • 12.2.3 TEMPUS AI, INC.
    • 12.2.4 LIFEBIT BIOTECH LTD.
    • 12.2.5 GENOOX
    • 12.2.6 DATA4CURE, INC.
    • 12.2.7 DEEP GENOMICS

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
  • TABLE 2 INDICATIVE LIST OF COLLABORATIONS AND PARTNERSHIPS IN AI IN BIOTECHNOLOGY MARKET (2021-2024)
  • TABLE 3 AI IN BIOTECHNOLOGY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 4 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 5 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 6 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 7 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 LIST OF PATENTS/PATENT APPLICATIONS IN AI IN BIOTECHNOLOGY MARKET, 2021-2024
  • TABLE 9 AI IN BIOTECHNOLOGY MARKET: INDICATIVE PRICING, BY DRUG DISCOVERY PROCESS
  • TABLE 10 AI IN BIOTECHNOLOGY MARKET: KEY CONFERENCES & EVENTS, 2024-2025
  • TABLE 11 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS (%)
  • TABLE 12 KEY BUYING CRITERIA FOR TOP 3 END USERS
  • TABLE 13 UNMET NEEDS IN AI IN BIOTECHNOLOGY MARKET
  • TABLE 14 END-USER EXPECTATIONS IN AI IN BIOTECHNOLOGY MARKET
  • TABLE 15 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 16 AI IN BIOTECHNOLOGY MARKET FOR END-TO-END SOLUTIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 17 AI IN BIOTECHNOLOGY MARKET FOR NICHE SOLUTIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 18 AI IN BIOTECHNOLOGY MARKET FOR TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 19 AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 20 AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 21 AI IN BIOTECHNOLOGY MARKET FOR CONSULTING SERVICES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 22 AI IN BIOTECHNOLOGY MARKET FOR IMPLEMENTATION SERVICES & ONGOING IT SUPPORT, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 23 AI IN BIOTECHNOLOGY MARKET FOR TRAINING & EDUCATION SERVICES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 24 AI IN BIOTECHNOLOGY MARKET FOR POST-SALES & MAINTENANCE SERVICES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 25 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 26 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 27 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 28 EXAMPLES OF AI TOOLS USED IN DRUG DISCOVERY
  • TABLE 29 AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 30 AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 31 AI IN BIOTECHNOLOGY MARKET FOR MOLECULAR DESIGN & OPTIMIZATION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 32 AI IN BIOTECHNOLOGY MARKET FOR BIOMARKER DISCOVERY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 33 AI IN BIOTECHNOLOGY MARKET FOR STRUCTURE-ACTIVITY RELATIONSHIP (SAR) MODELING, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 34 AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 35 AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 36 AI IN BIOTECHNOLOGY MARKET FOR TRIAL DESIGN, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 37 AI IN BIOTECHNOLOGY MARKET FOR SITE SELECTION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 38 AI IN BIOTECHNOLOGY MARKET FOR RECRUITMENT, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 39 AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DATA ASSESSMENT, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 40 AI IN BIOTECHNOLOGY MARKET FOR PREDICTIVE TOXICITY & RISK MONITORING, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 41 AI IN BIOTECHNOLOGY MARKET FOR MONITORING & DRUG ADHERENCE, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 42 AI IN BIOTECHNOLOGY MARKET FOR REAL-WORLD EVIDENCE (RWE) ANALYSIS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 43 AI IN BIOTECHNOLOGY MARKET FOR REGULATORY COMPLIANCE FUNCTIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 44 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 45 AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 46 AI IN BIOTECHNOLOGY MARKET FOR SUPPLY CHAIN PLANNING, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 47 AI IN BIOTECHNOLOGY MARKET FOR INVENTORY MANAGEMENT, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 48 AI IN BIOTECHNOLOGY MARKET FOR LOGISTICS OPTIMIZATION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 49 AI IN BIOTECHNOLOGY MARKET FOR DEMAND FORECASTING, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 50 AI IN BIOTECHNOLOGY MARKET FOR PREDICTIVE MAINTENANCE, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 51 AI IN BIOTECHNOLOGY MARKET FOR OTHER MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 52 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 53 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 54 AI IN BIOTECHNOLOGY MARKET FOR LAUNCH COORDINATION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 55 AI IN BIOTECHNOLOGY MARKET FOR PATIENT ENGAGEMENT, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 56 AI IN BIOTECHNOLOGY MARKET FOR MARKETING OPERATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 57 AI IN BIOTECHNOLOGY MARKET FOR PREDICTIVE PRICING, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 58 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 59 AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 60 AI IN BIOTECHNOLOGY MARKET FOR MEDICATION ADHERENCE, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 61 AI IN BIOTECHNOLOGY MARKET FOR ADVERSE EVENT REPORTING, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 62 AI IN BIOTECHNOLOGY MARKET FOR PATIENT MONITORING, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 63 AI IN BIOTECHNOLOGY MARKET FOR COMPLIANCE MONITORING, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 64 AI IN BIOTECHNOLOGY MARKET FOR PATIENT SUPPORT PROGRAMS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 65 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 66 AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 67 AI IN BIOTECHNOLOGY MARKET FOR RISK MANAGEMENT, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 68 AI IN BIOTECHNOLOGY MARKET FOR COMPLIANCE MONITORING, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 69 AI IN BIOTECHNOLOGY MARKET FOR SALES FORCE OPTIMIZATION, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 70 AI IN BIOTECHNOLOGY MARKET FOR OTHER CORPORATE FUNCTIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 71 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 72 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 73 AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 74 AI IN BIOTECHNOLOGY MARKET FOR PUBLIC CLOUD, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 75 AI IN BIOTECHNOLOGY MARKET FOR PRIVATE CLOUD, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 76 AI IN BIOTECHNOLOGY MARKET FOR MULTI-CLOUD, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 77 AI IN BIOTECHNOLOGY MARKET FOR HYBRID CLOUD, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 78 AI IN BIOTECHNOLOGY MARKET FOR ON-PREMISE SOLUTIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 79 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 80 AI IN BIOTECHNOLOGY MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 81 AI IN BIOTECHNOLOGY MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 82 AI IN BIOTECHNOLOGY MARKET FOR RESEARCH INSTITUTES & LABS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 83 AI IN BIOTECHNOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 84 AI IN BIOTECHNOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2022-2029 (USD MILLION)
  • TABLE 85 AI IN BIOTECHNOLOGY MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 86 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 87 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 88 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 89 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 90 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 91 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 92 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 93 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 94 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 95 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 96 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 97 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 98 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 99 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 100 US: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 101 US: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 102 US: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 103 US: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 104 US: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 105 US: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 106 US: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 107 US: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 108 US: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 109 US: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 110 US: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 111 US: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 112 US: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 113 CANADA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 114 CANADA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 115 CANADA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 116 CANADA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 117 CANADA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 118 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 119 CANADA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 120 CANADA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 121 CANADA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 122 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 123 CANADA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 124 CANADA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 125 CANADA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 126 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 127 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 128 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 129 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 130 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 131 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 132 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 133 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 134 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 135 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 136 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 137 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 138 EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 139 EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 140 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 141 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 142 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 143 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 144 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 145 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 146 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 147 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 148 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 149 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 150 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 151 GERMANY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 152 GERMANY: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 153 UK: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 154 UK: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 155 UK: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 156 UK: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 157 UK: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 158 UK: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 159 UK: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 160 UK: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 161 UK: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 162 UK: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 163 UK: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 164 UK: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 165 UK: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 166 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 167 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 168 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 169 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 170 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 171 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 172 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 173 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 174 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 175 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 176 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 177 FRANCE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 178 FRANCE: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 179 ITALY: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 180 ITALY: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 181 ITALY: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 182 ITALY: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 183 ITALY: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 184 ITALY: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 185 ITALY: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 186 ITALY: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 187 ITALY: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 188 ITALY: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 189 ITALY: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 190 ITALY: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 191 ITALY: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 192 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 193 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 194 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 195 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 196 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 197 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 198 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 199 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 200 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 201 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 202 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 203 SPAIN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 204 SPAIN: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 205 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 206 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 207 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 208 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 209 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 210 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 211 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 212 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 213 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 214 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 215 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 216 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 217 REST OF EUROPE: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 218 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 219 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 220 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 221 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 222 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 223 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 224 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 225 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 226 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 227 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 228 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 229 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 230 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 231 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 232 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 233 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 234 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 235 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 236 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 237 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 238 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 239 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 240 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 241 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 242 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 243 JAPAN: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 244 JAPAN: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 245 CHINA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 246 CHINA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 247 CHINA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 248 CHINA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 249 CHINA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 250 CHINA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 251 CHINA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 252 CHINA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 253 CHINA: AI IN BIOTECHNOLOGY MARKET, BY POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 254 CHINA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 255 CHINA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 256 CHINA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 257 CHINA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 258 INDIA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 259 INDIA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 260 INDIA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 261 INDIA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 262 INDIA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 263 INDIA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 264 INDIA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 265 INDIA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 266 INDIA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 267 INDIA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 268 INDIA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 269 INDIA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 270 INDIA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 271 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 272 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 273 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 274 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 275 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 276 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 277 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 278 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 279 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 280 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 281 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 282 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 283 SOUTH KOREA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 284 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 285 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 286 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 287 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 288 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 289 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 290 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 291 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 292 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 293 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 294 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 295 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 296 REST OF ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 297 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 298 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 299 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 300 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 301 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 302 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 303 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 304 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 305 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 306 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 307 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 308 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 309 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 310 LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 311 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 312 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 313 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 314 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 315 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 316 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 317 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 318 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 319 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 320 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 321 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 322 BRAZIL: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 323 BRAZIL: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 324 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 325 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 326 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 327 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 328 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 329 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 330 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 331 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 332 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 333 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 334 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 335 MEXICO: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 336 MEXICO: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 337 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 338 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 339 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 340 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 341 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 342 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 343 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 344 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 345 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 346 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 347 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 348 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 349 REST OF LATIN AMERICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 350 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 351 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 352 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 353 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 354 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 355 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 356 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 357 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 358 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 359 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 360 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 361 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 362 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 363 MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 364 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 365 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 366 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 367 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 368 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 369 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 370 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 371 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 372 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 373 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 374 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 375 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 376 GCC COUNTRIES: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 377 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2022-2029 (USD MILLION)
  • TABLE 378 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR SERVICES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 379 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2022-2029 (USD MILLION)
  • TABLE 380 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR RESEARCH & DEVELOPMENT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 381 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 382 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLINICAL DEVELOPMENT, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 383 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR MANUFACTURING & SUPPLY CHAIN FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 384 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR LAUNCH & COMMERCIAL FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 385 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR POST-MARKETING SURVEILLANCE & PATIENT SUPPORT FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 386 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CORPORATE FUNCTIONS, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 387 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2022-2029 (USD MILLION)
  • TABLE 388 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET FOR CLOUD-BASED SOLUTIONS MODE, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 389 REST OF MIDDLE EAST & AFRICA: AI IN BIOTECHNOLOGY MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 390 AI IN BIOTECHNOLOGY: DEGREE OF COMPETITION
  • TABLE 391 AI IN BIOTECHNOLOGY MARKET: OFFERING FOOTPRINT
  • TABLE 392 AI IN BIOTECHNOLOGY MARKET: FUNCTION FOOTPRINT
  • TABLE 393 AI IN BIOTECHNOLOGY MARKET: END-USER FOOTPRINT
  • TABLE 394 AI IN BIOTECHNOLOGY: REGION FOOTPRINT
  • TABLE 395 AI IN BIOTECHNOLOGY MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • TABLE 396 AI IN BIOTECHNOLOGY: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 397 AI IN BIOTECHNOLOGY MARKET: PRODUCT LAUNCHES & UPGRADES, JANUARY 2021-AUGUST 2024
  • TABLE 398 AI IN BIOTECHNOLOGY MARKET: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 399 AI IN BIOTECHNOLOGY MARKET: EXPANSIONS, JANUARY 2021-AUGUST 2024
  • TABLE 400 NVIDIA CORPORATION: COMPANY OVERVIEW
  • TABLE 401 NVIDIA CORPORATION: PRODUCTS OFFERED
  • TABLE 402 NVIDIA CORPORATION: PRODUCT LAUNCHES, JANUARY 2021-AUGUST 2024
  • TABLE 403 NVIDIA CORPORATION: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 404 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 405 ILLUMINA, INC.: PRODUCTS OFFERED
  • TABLE 406 ILLUMINA, INC.: PRODUCT LAUNCHES, JANUARY 2021-AUGUST 2024
  • TABLE 407 ILLUMINA, INC.: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 408 EXSCIENTIA: COMPANY OVERVIEW
  • TABLE 409 EXSCIENTIA: PRODUCTS OFFERED
  • TABLE 410 EXSCIENTIA: PRODUCT LAUNCHES, JANUARY 2021-AUGUST 2024
  • TABLE 411 EXSCIENTIA: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 412 EXSCIENTIA: OTHER DEVELOPMENTS, JANUARY 2021-AUGUST 2024
  • TABLE 413 SCHRODINGER, INC.: COMPANY OVERVIEW
  • TABLE 414 SCHRODINGER, INC.: PRODUCTS OFFERED
  • TABLE 415 SCHRODINGER, INC.: PRODUCT UPGRADES, JANUARY 2021-AUGUST 2024
  • TABLE 416 SCHRODINGER, INC.: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 417 RECURSION PHARMACEUTICALS, INC.: COMPANY OVERVIEW
  • TABLE 418 RECURSION PHARMACEUTICALS, INC.: PRODUCTS OFFERED
  • TABLE 419 RECURSION PHARMACEUTICALS, INC.: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 420 RECURSION PHARMACEUTICALS, INC.: EXPANSIONS, JANUARY 2021-AUGUST 2024
  • TABLE 421 SOPHIA GENETICS: COMPANY OVERVIEW
  • TABLE 422 SOPHIA GENETICS: PRODUCTS OFFERED
  • TABLE 423 SOPHIA GENETICS: PRODUCT LAUNCHES, JANUARY 2021-AUGUST 2024
  • TABLE 424 SOPHIA GENETICS: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 425 PREDICTIVE ONCOLOGY: COMPANY OVERVIEW
  • TABLE 426 PREDICTIVE ONCOLOGY: PRODUCTS OFFERED
  • TABLE 427 PREDICTIVE ONCOLOGY: PRODUCT LAUNCHES, JANUARY 2021-AUGUST 2024
  • TABLE 428 PREDICTIVE ONCOLOGY: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 429 BENEVOLENTAI: COMPANY OVERVIEW
  • TABLE 430 BENEVOLENTAI: PRODUCTS OFFERED
  • TABLE 431 BENEVOLENTAI: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 432 EUROFINS DISCOVERY: COMPANY OVERVIEW
  • TABLE 433 EUROFINS DISCOVERY: PRODUCTS OFFERED
  • TABLE 434 EUROFINS DISCOVERY: PRODUCT LAUNCHES, JANUARY 2021-AUGUST 2024
  • TABLE 435 EUROFINS DISCOVERY: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 436 EUROFINS DISCOVERY: EXPANSIONS, JANUARY 2021-AUGUST 2024
  • TABLE 437 XTALPI INC.: COMPANY OVERVIEW
  • TABLE 438 XTALPI INC.: PRODUCTS OFFERED
  • TABLE 439 XTALPI INC.: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 440 DNANEXUS, INC.: COMPANY OVERVIEW
  • TABLE 441 DNANEXUS, INC.: PRODUCTS OFFERED
  • TABLE 442 DNANEXUS, INC.: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 443 DNANEXUS, INC: OTHER DEVELOPMENTS, JANUARY 2021-AUGUST 2024
  • TABLE 444 NUMEDII, INC.: COMPANY OVERVIEW
  • TABLE 445 NUMEDII, INC.: PRODUCTS OFFERED
  • TABLE 446 BPGBIO, INC.: COMPANY OVERVIEW
  • TABLE 447 BPGBIO, INC.: PRODUCTS OFFERED
  • TABLE 448 BPGBIO, INC.: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 449 IKTOS: COMPANY OVERVIEW
  • TABLE 450 IKTOS: PRODUCTS OFFERED
  • TABLE 451 IKTOS: DEALS, JANUARY 2021-AUGUST 2024
  • TABLE 452 INSILICO MEDICINE: COMPANY OVERVIEW
  • TABLE 453 INSILICO MEDICINE: PRODUCTS OFFERED
  • TABLE 454 LOGICA: COMPANY OVERVIEW
  • TABLE 455 LOGICA: PRODUCTS OFFERED
  • TABLE 456 AMERICAN CHEMICAL SOCIETY: COMPANY OVERVIEW
  • TABLE 457 AMERICAN CHEMICAL SOCIETY: PRODUCTS OFFERED
  • TABLE 458 AGANITHA AI INC.: COMPANY OVERVIEW
  • TABLE 459 AGANITHA AI INC.: PRODUCTS OFFERED
  • TABLE 460 AGANITHA AI INC.: DEALS, JANUARY 2021-AUGUST 2024

List of Figures

  • FIGURE 1 AI IN BIOTECHNOLOGY MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 PRIMARY SOURCES
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 6 TOP-DOWN APPROACH
  • FIGURE 7 AI IN BIOTECHNOLOGY MARKET: CAGR PROJECTIONS
  • FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 9 DATA TRIANGULATION
  • FIGURE 10 AI IN BIOTECHNOLOGY MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION)
  • FIGURE 11 AI IN BIOTECHNOLOGY MARKET, BY FUNCTION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 AI IN BIOTECHNOLOGY MARKET, BY DEPLOYMENT MODE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 AI IN BIOTECHNOLOGY MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 AI IN BIOTECHNOLOGY MARKET: GEOGRAPHICAL SNAPSHOT
  • FIGURE 15 GROWING FOCUS ON COST-EFFECTIVE PROCESSES AND FAVORABLE GOVERNMENT SUPPORT AND FUNDING TO DRIVE MARKET
  • FIGURE 16 NORTH AMERICA TO DOMINATE AI IN BIOTECHNOLOGY MARKET DURING FORECAST PERIOD
  • FIGURE 17 PHARMACEUTICAL COMPANIES IN NORTH AMERICA ACCOUNTED FOR LARGEST MARKET SHARE IN 2023
  • FIGURE 18 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 19 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
  • FIGURE 20 AI IN BIOTECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 21 AI IN BIOTECHNOLOGY MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 22 AI IN BIOTECHNOLOGY MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 23 AI IN BIOTECHNOLOGY MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 24 PATENT PUBLICATION TRENDS IN AI IN BIOTECHNOLOGY MARKET, 2015-2024
  • FIGURE 25 PATENT ANALYSIS OF AI IN BIOTECHNOLOGY MARKET, JANUARY 2015-AUGUST 2024
  • FIGURE 26 EVOLUTION OF AI IN BIOTECHNOLOGY MARKET
  • FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF TOP 3 END USERS
  • FIGURE 28 KEY BUYING CRITERIA FOR TOP 3 END USERS
  • FIGURE 29 TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 30 AI IN BIOTECHNOLOGY MARKET: INVESTMENT & FUNDING SCENARIO
  • FIGURE 31 MARKET POTENTIAL OF AI/GENERATIVE AI ON AI IN BIOTECHNOLOGY SOLUTIONS
  • FIGURE 32 NUMBER OF AI-DISCOVERED MOLECULES IN CLINICAL TRIALS
  • FIGURE 33 NORTH AMERICA: AI IN BIOTECHNOLOGY MARKET SNAPSHOT
  • FIGURE 34 ASIA PACIFIC: AI IN BIOTECHNOLOGY MARKET SNAPSHOT
  • FIGURE 35 KEY DEVELOPMENTS OF MAJOR PLAYERS BETWEEN JANUARY 2021 AND JUNE 2024
  • FIGURE 36 REVENUE ANALYSIS OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET, 2019-2023 (USD BILLION)
  • FIGURE 37 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET (2023)
  • FIGURE 38 RANKING OF KEY PLAYERS IN AI IN BIOTECHNOLOGY MARKET, 2023
  • FIGURE 39 AI IN BIOTECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 40 AI IN BIOTECHNOLOGY MARKET: COMPANY FOOTPRINT
  • FIGURE 41 AI IN BIOTECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
  • FIGURE 42 EV/EBITDA OF KEY VENDORS
  • FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF AI IN BIOTEHNOLOGY SOLUTION VENDORS
  • FIGURE 44 AI IN BIOTECHNOLOGY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 45 NVIDIA CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 46 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 47 EXSCIENTIA: COMPANY SNAPSHOT (2023)
  • FIGURE 48 SCHRODINGER, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 49 RECURSION PHARMACEUTICALS, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 50 SOPHIA GENETICS: COMPANY SNAPSHOT (2022)
  • FIGURE 51 PREDICTIVE ONCOLOGY: COMPANY SNAPSHOT (2023)
  • FIGURE 52 BENEVOLENTAI: COMPANY SNAPSHOT (2023)
  • FIGURE 53 EUROFINS DISCOVERY: COMPANY SNAPSHOT (2023)
  • FIGURE 54 XTALPI INC.: COMPANY SNAPSHOT (2023)